Profile Category: Madrid 2020 Speakers

William Muecke

William Muecke

William Muecke is a co-founding managing member of Artemis Growth Partners LLC, an impact-oriented private equity platform 100% dedicated to investing in the cannabis industry on a worldwide basis. Artemis Growth Partners oversees US $150+ million in discretionary assets under management (AUM) invested in the global cannabis supply chain, including branded products, distributors, value-added service providers, ancillary operators, and science-driven research and development platforms.

Ion Arocena

Ion Arocena

Ion Arocena is the Managing Director of ASEBIO, the Spanish biotech industry association. He is a specialist in the evaluation of projects, patents and spin-offs of biotechnology. Since 2009, he teaches Biotechnology Start-ups Financing classes at CESIF (Centro de Estudios Superiores de la Industria Farmacéutica).

Camilo Botero

Camilo Botero

Camilo is a Senior Investment Advisor for Procolombia, a government agency in charge of promoting Colombian non-traditional exports, international tourism and foreign investment to Colombia. Before Procolombia, Camilo was Chief Financial Officer (CFO) and Chairman of the Board of Directors at GreenFuel, a biofuels company in Spain and previously he worked as Head of International Commodity Trade Operations and Sustainability and as a Financial Advisor and Lead Mutual Fund Trader.

Kingsley Wilson

Kingsley Wilson

Kingsley has worked in the financial and investment services industry over the last 25 years, spending 10 years at two large investment banks as a research analyst focused on company analysis, portfolio construction, risk mitigation and institutional sales. As a founding partner of London based Chrystal Capital Partners, he has spent the past 15 years advising companies on raising over US$1.5bn of capital across over 100+ public and private transactions. Over the past four years he has led multiple cannabis investments raising over US$200m in capital from Chrystal’s network of global family offices for a number of different cannabis focused companies. Chrystal Capital is now launching a US$200m cannabis fund called Verdite Capital Fund I to invest across multiple verticals, geographies and stages in the global cannabis industry.

Hélène Moore

Hélène Moore

During her 20 years of experience in the life science industry, Hélène has been involved in the research and development, partnering and commercialization of medicines around the world, from Bayer and beyond. Now based in Paris, Hélène is the managing director of Aurora France, a subsidiary of Aurora Europe. In her role, she is in charge of building a strategy for establishing Aurora’s role in the emerging French market, in particular through dialogue with public and private institutions involved in health and market access. Hélène holds a degree in Biochemistry from the University of Montreal and an executive MBA from the University of Quebec in Montreal.

Daniel Mediavilla

Daniel Mediavilla

Daniel Mediavilla holds a degree in Audiovisual Communication by the University of Navarra and is one of the founders of Materia, the Science and Technology news web which currently conforms the Science section of El País. Previously, Daniel worked as advisor to the Secretary of State for Research, Felipe Pétriz, in the Ministry of Science and Innovation and in Science Communication for the newspapers ABC and Público.

Andrew Scott

Andrew Scott

Andrew is an experienced market commentator helping businesses to get in front of the right investors at the right time with the right message. Andrew has 10 years on-screen experience presenting with the likes of Thompson Reuters, Sky News and ITV. He is an expert on growth stocks – analysing and reporting on global markets, derivatives, equities and commodities.

Luís Mendão

Luís Mendão

Luís Mendão concluded his studies in biochemistry in 1983 at the University Pierre et Marie Curie, in Paris. Luís Mendão is currently the Chair of the Board of GAT - Treatment Activist Group, an NGO founded in 2001, focusing on prevention, early diagnosis, treatment and care of HIV/AIDS, viral hepatitis while working with key populations. He is also the founder and on the Board of Directors of the Anti-Prohibitionist Association (SOMA-APA). Currently, he co-chairs the Civil Society Forum on HIV/AIDS at the European Commission and he’s Chair of the European AIDS Treatment Group (EATG). Luís Mendão also integrates to the Steering Committee of the HIVPORTUGAL initiative. In the last ten years, he has been community consultant of the Regional Office of the World Health Organization Europe (WHO Europe), EMCDDA and ECDC. Luís Mendão was diagnosed with HIV and HCV in 1996.

José Luis Martin

José Luis Martin

José Luis Martin is a Partner at the law firm Baker Tilly in Spain. José Luis holds 10+ years’ experience in cross-border transactions, M&A, commercial contracts and corporate law. He personally handled the proceedings with the Spanish regulator that led to the first ever cannabis license in Spain.

Yona Cymerman

Yona Cymerman

Yona Cymerman is an entrepreneur and co-founder of Can Innovations, a company focused on introducing innovation to the global cannabis market. The company is now establishing an international innovation accelerator for cannabis related technologies, in conjunction with global names in cannabis and intersecting industries. Prior to her role at Can Innovations, Yona ran her own marketing strategy firm, held the role of VP Strategic Marketing at Ruder Finn and was an adjunct faculty member at the Interdisciplinary Center in Herzliya, Israel.

Jorge Fernandez

Jorge Fernandez

Dedicated to research for over 5 years, Jorge founded in 2006 a Hi-tech firm in San Sebastian. In 2008, he founded Hermes Medical Engineering S.L., committed to the reseach and design of devices for the administration of active principles in vapor mediums. The first device, called MiniVAP, is sold all over the world for its therapeutic effects. At present, Hermes Medical S.L. is developing a medical vaporizer for Bedrocan BV, that will be used in clinical trials.

Manuel Guzmán

Manuel Guzmán

Manuel Guzmán is Professor of Biochemistry and Molecular Biology at the Complutense University of Madrid and a member of the Royal National Academy of Pharmacy. His pre- and postdoctoral research focused on the study of lipid metabolism in the liver and brain. At the end of the 90s a new line of research focused on the study of how cannabinoids act in the body began, with special emphasis on the molecular basis of such action in the fields of oncology and neurodegeneration. This work has allowed characterizing new effects and mechanisms of action of cannabinoids, as well as suggesting possible pathophysiological implications derived from them.

João Gama

João Gama

João Gama is lawyer and policy advisor based in Lisbon. As a partner at Gama Glória, a law firm based in Lisbon, and a senior advisor at the Albright Stonebridge Group, a consulting firm based in Washington D.C., he has been focusing on disruptive, innovative and frontier business models, in the technology, transportation, and healthcare sectors, including cannabis. João is affiliated with the Law School of the Portuguese Catholic University, where he regularly teaches on tax and regulatory issues, having recently taught the first course on the Regulation of Medical Cannabis in the country. João is a member of the Business Ethics Committee of the Portuguese Pharma Association and served as a member of the Portuguese Government as Secretary of State for Local Government and as a political advisor to the President.

José Luis Adrio

José Luis Adrio

Dr. José Luis Adrio holds a Ph.D. in Pharmacy from the University of Santiago de Compostela and an Organization & Management of Technological Innovation program from the Polytechnic University of Madrid. He has been a postdoctoral researcher at the Department of Biology at MIT, Cambridge, EE.UU and has developed his profesional activity in several biotech companies such as Antibióticos de León, Puleva Biotech, Neuron Biopharma, Neol Bio and Evolgene. Currently he is the R&D director at ADL Biopharma.

Expert in the development of microbial biotechnology processes from laboratory to pilot scale, molecular biology techniques and metabolic engineering. He has also deep knowledge about development programs of microbial strains as well as management of R&D projects.

James O’Dowd

James O’Dowd

James established the European Alliance for Medicinal Cannabis (EAMC) in February 2019 with the central aim of promoting a sensible policy towards medicinal cannabis in the EU27. Prior to establishing EAMC, in his capacity as Managing Director of TPA Research, James advised several firms on the regulatory landscape governing medicinal cannabis in several European markets, no two of which were alike. Prior to joining TPA as a government affairs analyst in 2012, James worked in the European Parliament as a political adviser and head of research to Vice-Chairman of the European Conservatives and Reformists Group, Geoffrey Van Orden MEP.

Beau Epperly

Beau Epperly

Beau Epperly advises startup-business clients in all aspects of the startup cycle; from formation to exit. He guides mature companies through complex securities and tax regulatory matters. He and his team have led a variety of funding deals for startups and recapitalization funding for existing businesses.

Luis de Palacio

Luis de Palacio

Luis de Palacio is a pharmacist and lawyer. He owns a pharmacy in Pozuelo de Alarcón, and is President of FEFE, the Spanish Federation of Pharmacies. Mr de Palacio is also a member of the College of Pharmacists in Madrid, where he participates in reviewing functions in the Resources Commission.

Prof. José Javier Fernandez Ruiz

Prof. José Javier Fernandez Ruiz

José Javier Fernández-Ruiz is Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine at the Complutense University of Madrid. He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University. The main activity of this group is the study of the therapeutic potential of cannabinoids in several neurological diseases, mainly neurodegenerative, activity addressed to the design, synthesis and biological characterization of novel cannabinoids with neuroprotective profile, and to test their therapeutic efficacy at preclinical and clinical levels. Professor Fernandez is also a member of the Editorial Board in the British Journal of Pharmacology.

Hannah Deacon

Hannah Deacon

Hannah Deacon is the mother of Alfie Dingley, a six-year-old boy with a rare form of epilepsy. When Hannah and Alfie moved to Holland for five months to access medicine containing THC, Alfie's condition improved dramatically, after which Hannah became the first person to legally enter UK with cannabis oil to help her son in June 2018.

Salvador Garcia-Ruiz

Salvador Garcia-Ruiz

Salvador Garcia-Ruiz is the Managing Director of Aurora Medicine Spain since 2019. His experience includes consulting, banking, education and, more recently, media.

  • 1
  • 2